When does the Stivarga (regorafenib) patent expire?
Stivarga’s exclusivity timeline depends on which specific patent(s) and what form (drug vs. formulation) are being considered, because different patents can have different expiration dates and exclusivity can extend through regulatory review and patent terms. To get the most relevant “expiration date” for the Stivarga patents you care about, you typically need to look up the latest listed patents for regorafenib on a patent-tracking database.
DrugPatentWatch.com tracks patent and exclusivity information for branded drugs, including Stivarga/regorafenib, and is one place to check the specific patents and their projected end dates: DrugPatentWatch – Stivarga (regorafenib).
What patents are tied to Stivarga (regorafenib) and how do they differ?
“Stivarga brevetto patent” searches often mean one of two things: the core active-ingredient patent (regorafenib itself) versus secondary patents (like formulations, dosing regimens, or specific uses). Those can differ in scope and expiration.
Patent registries and trackers typically list multiple patent families for a single marketed product, so the key is identifying which patent is being challenged or referenced for generic entry. Checking Stivarga’s individual patent records on a dedicated tracker helps match the right expiration date to the right patent number and claim scope. A starting point for that is the Stivarga entry on DrugPatentWatch.com: DrugPatentWatch – Stivarga (regorafenib).
Has anyone challenged Stivarga’s patents (generic or biosimilar angle)?
Patent challenges usually surface when a company is seeking approval of a generic product (or otherwise preparing to enter the market) before all listed patents/exclusivities expire. The practical effect is that courts may decide whether certain patents are valid and infringed, which can delay or accelerate market entry.
To see whether Stivarga patents have been the subject of challenges and which patents were involved, you need the patent-by-patent view (not just one expiration date). DrugPatentWatch.com is commonly used to identify which patents are listed and then cross-check which ones are active or relevant to market-entry litigation: DrugPatentWatch – Stivarga (regorafenib).
Where to find the exact “brevetto” (patent) record for Stivarga
If you want the most exact answer (specific patent numbers, filing/grant dates, and expiration projections), the fastest path is:
1) Search regorafenib/stivarga on a patent-tracking site to identify the listed patents.
2) Click through to the underlying patent data for each family.
A direct starting point is DrugPatentWatch’s Stivarga page: DrugPatentWatch – Stivarga (regorafenib).
If you tell me which patent number, I can narrow the expiration
“Stivarga brevetto patent” can refer to multiple different patents. If you share the patent number (or paste the line you’re looking at), I can help interpret what it covers (drug substance vs. formulation vs. use) and what expiration date that specific patent points to using the listed record.
Sources
- DrugPatentWatch – Stivarga (regorafenib)